Daniel E Spratt1, Payal D Soni1, Patrick W McLaughlin2, Gregory S Merrick3, Richard G Stock4, John C Blasko5, Michael J Zelefsky6. 1. Department of Radiation Oncology, University of Michigan, Ann Arbor, MI. 2. Department of Radiation Oncology, University of Michigan, Ann Arbor, MI. Electronic address: mclaughb@med.umich.edu. 3. Schiffler Cancer Center, Department of Radiation Oncology, Wheeling Jesuit University, Wheeling, WV; Department of Urology, Wheeling Hospital, Wheeling, WV. 4. Department of Radiation Oncology, The Icahn School of Medicine at Mount Sinai, New York, NY. 5. Retired, Seattle, WA. 6. Department of Radiation Oncology, Memorial Sloan Kettering, New York, NY.
Abstract
PURPOSE: To review outcomes for high-risk prostate cancer treated with combined modality radiation therapy (CMRT) utilizing external beam radiation therapy (EBRT) with a brachytherapy boost. METHODS AND MATERIALS: The available literature for high-risk prostate cancer treated with combined modality radiation therapy was reviewed and summarized. RESULTS: At this time, the literature suggests that the majority of high-risk cancers are curable with multimodal treatment. Several large retrospective studies and three prospective randomized trials comparing CMRT to dose-escalated EBRT have demonstrated superior biochemical control with CMRT. Longer followup of the randomized trials will be required to determine if this will translate to a benefit in metastasis-free survival, disease-specific survival, and overall survival. Although greater toxicity has been associated with CMRT compared to EBRT, recent studies suggest that technological advances that allow better definition and sparing of critical adjacent structures as well as increasing experience with brachytherapy have improved implant quality and the toxicity profile of brachytherapy. The role of androgen deprivation therapy is well established in the external beam literature for high-risk disease, but there is controversy regarding the applicability of these data in the setting of dose escalation. At this time, there is not sufficient evidence for the omission of androgen deprivation therapy with dose escalation in this population. Comparisons with surgery remain limited by differences in patient selection, but the evidence would suggest better disease control with CMRT compared to surgery alone. CONCLUSIONS: Due to a series of technological advances, modern combination series have demonstrated unparalleled rates of disease control in the high-risk population. Given the evidence from recent randomized trials, combination therapy may become the standard of care for high-risk cancers.
PURPOSE: To review outcomes for high-risk prostate cancer treated with combined modality radiation therapy (CMRT) utilizing external beam radiation therapy (EBRT) with a brachytherapy boost. METHODS AND MATERIALS: The available literature for high-risk prostate cancer treated with combined modality radiation therapy was reviewed and summarized. RESULTS: At this time, the literature suggests that the majority of high-risk cancers are curable with multimodal treatment. Several large retrospective studies and three prospective randomized trials comparing CMRT to dose-escalated EBRT have demonstrated superior biochemical control with CMRT. Longer followup of the randomized trials will be required to determine if this will translate to a benefit in metastasis-free survival, disease-specific survival, and overall survival. Although greater toxicity has been associated with CMRT compared to EBRT, recent studies suggest that technological advances that allow better definition and sparing of critical adjacent structures as well as increasing experience with brachytherapy have improved implant quality and the toxicity profile of brachytherapy. The role of androgen deprivation therapy is well established in the external beam literature for high-risk disease, but there is controversy regarding the applicability of these data in the setting of dose escalation. At this time, there is not sufficient evidence for the omission of androgen deprivation therapy with dose escalation in this population. Comparisons with surgery remain limited by differences in patient selection, but the evidence would suggest better disease control with CMRT compared to surgery alone. CONCLUSIONS: Due to a series of technological advances, modern combination series have demonstrated unparalleled rates of disease control in the high-risk population. Given the evidence from recent randomized trials, combination therapy may become the standard of care for high-risk cancers.
Authors: Kilian E Salerno; Baris Turkbey; Liza Lindenberg; Esther Mena; Erica E Schott; Alexandra K Brennan; Soumyajit Roy; Uma Shankavaram; Krishnan Patel; Theresa Cooley-Zgela; Yolanda McKinney; Bradford J Wood; Peter A Pinto; Peter Choyke; Deborah E Citrin Journal: Brachytherapy Date: 2022-05-04 Impact factor: 2.441
Authors: Kathryn R Tringale; Renee L Gennarelli; Erin F Gillespie; Aaron P Mitchell; Michael J Zelefsky Journal: Cancer Invest Date: 2021-01-08 Impact factor: 2.176
Authors: Jörg S Zimmermann; Rudolf Osieka; Thorsten Bruns; Helge Hollberg; Bastian Wiechmann; Olaf Netzbandt; Jörg Sablotny; Michael Malade; Matthias Heitz; Fritz Bernhardt; Jörg Tiemann; Marc Wilkens; Tom Brüske; Utz Welker; Volker Heinemann; Petra Zimmermann; Salvador Fernandez de la Maza; Dietrich Pfeiffer; Prof Roland Tauber; Dorothea Thomas; Christos Moustakis Journal: J Contemp Brachytherapy Date: 2018-08-31
Authors: Gregory S Merrick; Ava Tennant; Kent E Wallner; Robert Galbreath; Wayne M Butler; Ryan Fiano; Edward Adamovich Journal: J Contemp Brachytherapy Date: 2017-10-19